<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drug regimens for treatment of cutaneous leishmaniasis in adults&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drug regimens for treatment of cutaneous leishmaniasis in adults<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Drug regimens for treatment of cutaneous leishmaniasis in adults<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Drug</td> <td class="subtitle1">Dose</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Local therapy</td> </tr> <tr> <td class="indent1" rowspan="2">Pentavalent antimonials*</td> <td>Sodium stibogluconate</td> <td>0.5 to 2 mL of 100 mg/mL pentavalent antimony <span class="nowrap_whitespace">(Sb<sup>5+</sup>)</span> intralesionally every 7 days until healed (treat up to 3 weeks)</td> </tr> <tr> <td>Meglumine antimoniate<sup>¶</sup></td> <td>0.5 to 2 mL of 81 mg/mL pentavalent antimony <span class="nowrap_whitespace">(Sb<sup>5+</sup>)</span> intralesionally every 7 days until healed (treat up to 3 weeks)</td> </tr> <tr> <td class="indent1" rowspan="2">Paromomycin<sup>Δ</sup></td> <td>Paromomycin ointment</td> <td>Apply topically to lesions twice daily for 10 days, rest for 10 days, then reapply for 10 days</td> </tr> <tr> <td>Paromomycin cream (15%)</td> <td>Apply topically to lesions once daily for 20 days</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Oral systemic therapy</td> </tr> <tr> <td class="indent1" rowspan="2">Azoles</td> <td>Fluconazole</td> <td>200 to 400 mg orally once daily for 6 weeks</td> </tr> <tr> <td>Ketoconazole</td> <td>600 mg orally once daily for 28 days</td> </tr> <tr> <td class="indent1">Miltefosine</td> <td>Miltefosine<sup>◊</sup></td> <td>2.5 mg/kg (maximum 150 mg) orally in three divided doses for 28 days; if weight is 30 to 44 kg, use 50 mg orally twice daily</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Parenteral systemic therapy</td> </tr> <tr> <td class="indent1" rowspan="2">Pentavalent antimonials*</td> <td>Sodium stibogluconate</td> <td>20 mg <span class="nowrap_whitespace">Sb<sup>V</sup>/kg/day</span> intravenously or intramuscularly for 10 to 20 days<sup>§</sup></td> </tr> <tr> <td>Meglumine antimoniate</td> <td>20 mg <span class="nowrap_whitespace">Sb<sup>V</sup>/kg/day</span> intravenously or intramuscularly for 10 to 20 days<sup>§</sup></td> </tr> <tr> <td class="indent1" rowspan="2">Amphotericin</td> <td>Amphotericin B deoxycholate</td> <td>0.5 to 1 mg/kg intravenously dosed daily or every other day for a cumulative total dose of 15 to 30 mg/kg</td> </tr> <tr> <td>Liposomal amphotericin B (AmBisome)</td> <td>3 mg/kg intravenously daily for 6 to 7 doses</td> </tr> <tr> <td class="indent1">Pentamidine</td> <td>Pentamidine isethionate</td> <td>7 mg/kg pentamidine salt intravenously or intramuscularly weekly for 3 doses<sup>¥</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">Agents listed, dose regimens, and combinations are effective only against certain <em>Leishmania</em> species/strains and only in certain areas of the world. Refer to the UpToDate topic on treatment of cutaneous leishmaniasis for the therapeutic approach to cutaneous leishmaniasis. Pediatric dosing is summarized separately.</div><div class="graphic_footnotes"><p>Sb<sup>V</sup>: pentavalent antimony.</p>
<p>* Not commercially available in the United States. Meglumine antimoniate may be obtained via an investigational new drug <a href="https://www.astmh.org/blog/september-2022/instructions-for-acquiring-glucantime-(meglumine-a" target="_blank">application</a> to the US Food and Drug Administration (FDA).</p>
<p>¶ Effective dose for weight &gt;75 kg may require higher dose off-label (with attendant gastrointestinal effects), aiming for &gt;2.5 mg/kg dose.</p>
<p>Δ Topical paromomycin is not available in the United States. The paromomycin preparation needs to be specially prepared by a compounding pharmacy. Two compound preparations are available from licensed compounding pharmacies: 15% paromomycin ointment with methylbenzethonium chloride and 15% paromomycin cream with gentamicin. Refer to Lexicomp paromomycin monograph for further details.</p>
<p>◊ Miltefosine is FDA approved and commercially available in the United States. Miltefosine should not be used in females of childbearing age unless a validated contraceptive method is used during treatment and for at least 5 months following treatment.</p>
<p>§ Doses are expressed as mg of pentavalent antimony content. Duration of 10 days is appropriate for treatment of relatively mild disease with evidence of clinical response by day 10; otherwise, the duration should be extended. Duration of 20 days is appropriate for treatment of CL due to species known to cause mucosal disease. Meglumine antimoniate has 81 mg <font class="nowrap_whitespace">Sb<sup>V</sup>/mL,</font> while sodium stibogluconate (SSG) contains 100 mg <font class="nowrap_whitespace">Sb<sup>V</sup>/mL.</font> Intravenous treatment is usually diluted at least 10-fold with 5% dextrose in water and SSG is filtered.</p>
¥ Pentam 300 contains 300 mg of pentamidine isethionate salt per vial. This is 171 mg pentamidine base.</div><div class="graphic_reference">References:
<ol>
<li>Goto H, Laulett Lindoso JA. Cutaneous and mucocutaneous leishmaniasis. Inf Dis Clin N Am 2012; 26:293.</li>
<li>Centers for Disease Control and Prevention. Parasites – Leishmaniasis. Available at: <a href="https://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx" target="_blank">http://www.cdc.gov/parasites/leishmaniasis/health_professionals/index.html#tx</a> (Accessed September 2022).</li>
</ol></div><div id="graphicVersion">Graphic 88693 Version 20.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
